Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
According to the CDC, from 2017-2020, almost 42% of adults over 20 were obese
Side Effects in Men vs Women Most of the incidence numbers above come from the trials in premenopausal women that supported the FDA approval, where nausea, flushing, and headache dominated
Berberine, by contrast, works through multiple pathways including AMPK activation and mitochondrial function, independently affecting glucose metabolism and lipid profiles without direct receptor activation
Modulation of cell growth and cisplatin sensitivity by membrane -glutamyltransferase in melanoma cells
